tiprankstipranks
Peijia Medical Maintains Rights Post-Partner Merger
Company Announcements

Peijia Medical Maintains Rights Post-Partner Merger

Peijia Medical Ltd. (HK:9996) has released an update.

Pick the best stocks and maximize your portfolio:

Peijia Medical Limited has announced the acquisition of its licensing partner, JenaValve Technology, Inc., by Edwards Lifesciences Corporation, maintaining Peijia’s exclusive rights to develop and commercialize the TaurusTrio™ Transcatheter Heart Valve System in Greater China. The merger does not affect Peijia’s ongoing clinical trial in China or its rights to the licensed technology, with the company expressing confidence in the technology’s prospects for treating heart conditions. Investors are advised to exercise caution when dealing in Peijia Medical’s shares as the development and market success of TaurusTrio™ is not guaranteed.

For further insights into HK:9996 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks HongKong Auto-Generated NewsdeskPeijia Medical Advances with TAVR System in Hong Kong
TipRanks HongKong Auto-Generated NewsdeskPeijia Medical Announces Resignation of Non-Executive Director
TipRanks HongKong Auto-Generated NewsdeskPeijia Medical Unveils Board Structure and Governance
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App